4C Biomed
Pre-clinical immuno-oncology company finding immune targets and developing antibody drugs for cancer treatment
Highlights
- New on EvolcAdded 2026-11-01
About 4C Biomed
4C Biomed discovers immune targets for cancer and develops drugs that modulate them. Its screening platform combines patient-derived tumour cultures or tumour digests with the same patient's immune cells (TILs or PBMCs) and clinical data annotations to identify and prioritise targets.
Its lead candidate, anti-4CB1, is a fully human anti-HVEM monoclonal antibody that blocks the HVEM-BTLA and HVEM-CD160 interactions. The drug has completed IND-enabling studies and is planned to enter clinical Phase I in early 2027. The company states that over 20% of the immune targets it discovered have reached clinical trials by pharmaceutical companies, and it invites pharma partnerships. Several patents have been filed, and some of the research is supported by an IIA grant.
The company is registered as 4C BIOMED LIMITED in London, United Kingdom, and was founded in 2020. Its leadership includes Dr. Alan Barge, MD, as Chief Executive Officer, and a team of researchers and clinicians with backgrounds at academic medical centres and pharmaceutical companies.
Product: Immunological screening platform for cancer immune targets and the anti-4CB1 anti-HVEM monoclonal antibody drug candidate.
Jobs at 4C Biomed
Leadership
- Anthony Angel · Chairman & Co-founderSource: company website
- Eyal Greenberg · Chief Development Officer & Scientific Co-founderSource: company website
- Gal Markel · Chief Scientific Officer & Co-founderSource: company website
- Jacob Schachter · Chief Medical Officer & Co-founderSource: company website
- Alan Barge · Chief Executive OfficerSource: company website
More biotech & pharma companies
Abingdon Analytical
UKAS-accredited stability, shelf-life and method validation testing for diagnostic and medical device developersYoung companyNew on EvolcActimed Therapeutics
Clinical-stage drug developer targeting cancer cachexia and muscle wasting with S-pindolol benzoate in Phase 2New on EvolcAds Biotec
Automated laboratory instruments, consumables and purification solutions for cytogenetic, pathology and research labsNew on EvolcAixcell
Autonomous cell culture system running routine and multi-project cell-based workflows for AI/ML data generationNew on EvolcAlimera Sciences
Develops and commercialises ophthalmic medicines for patients with chronic retinal diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- LiteSpeedHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.